Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.54 |
| ▸ | LDHA | P00338 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | JUN | P05412 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241738 | 0.94 | LTA4H (0.49) | PTGS1LTA4HLDHATSHRALOX15 | |
| SCHEMBL1874328 | 0.91 | LTA4H (0.65) | PTGS1LTA4HLDHATSHRALOX15 | |
| Acetic Acid SCHEMBL3241741 | 0.82 | FOS (0.55) | LTA4HLDHATSHRALOX15NR3C1 | |
| SCHEMBL21402299 | 0.79 | ALOX15 (0.62) | TSHRALOX15NR3C1JUNNFKB1 | |
| SCHEMBL676400 | 0.79 | FOS (0.62) | PTGS1TSHRALOX15NR3C1JUN | |
| SCHEMBL357406 | 0.79 | PTGS1 (0.64) | PTGS1LTA4HTSHRNR3C1JUN | |
| SCHEMBL5133639 | 0.78 | PTGS1 (0.68) | PTGS1LTA4HLDHATSHRNR3C1 | |
| SCHEMBL10705215 | 0.77 | LDHA (0.61) | PTGS1LDHATSHRALOX15NR3C1 | |
| SCHEMBL10426009 | 0.77 | LDHA (0.61) | PTGS1LDHATSHRALOX15NR3C1 | |
| SCHEMBL10426010 | 0.77 | LDHA (0.61) | PTGS1LDHATSHRALOX15NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517880-B1 | PRODUCTION OF CIS-PELLITORIN AND USE AS A FLAVOURING | SYMRISE AG (DE) | 2011-01-05 | — | — | EP | claimed |
| EP-2496204-A2 | ORAL COMPOSITIONS FOR TREATMENT OF DRY MOUTH | The Procter & Gamble Company (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2496205-A2 | ORAL COMPOSITIONS FOR TREATMENT OF DRY MOUTH | The Procter & Gamble Company (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011056748-A2 | ORAL COMPOSITIONS FOR TREATMENT OF DRY MOUTH | THE PROCTER & GAMBLE COMPANY (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056759-A2 | ORAL COMPOSITIONS FOR TREATMENT OF DRY MOUTH | THE PROCTER & GAMBLE COMPANY (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110104080-A1 | Oral Compositions for Treatment of Dry Mouth | THE PROCTER & GAMBLE COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-20110104081-A1 | Oral Compositions for Treatment of Dry Mouth | THE PROCTER & GAMBLE COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-7482479-B2 | Production of cis-pellitorin and use as a flavouring | SYMRISE GMBH & CO., KG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20080242740-A1 | AROMA COMPOSITIONS OF ALKAMIDES WITH HESPERETIN AND/OR 4-HYDROXYDIHYDROCHALCONES AND SALTS THEREOF FOR ENHANCING SWEET SENSORY IMPRESSIONS | SYMRISE GMBH & CO. KG (DE) | 2008-10-02 | — | — | US | disclosed |
| US-20080008660-A1 | Antimicrobially active compounds for treating bad breath | SYMRISE GMBH & CO. KG (DE) | 2008-01-10 | — | — | US | disclosed |
| US-20050234132-A1 | Production of cis-pellitorin and use as a flavouring | SYMRISE AG (DE) | 2005-10-20 | — | — | US | disclosed |
| US-20050208084-A1 | Use of alkylamidomandelates as flavourings | SYMRISE GMBH & CO. KG (DE) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104081-A1 | Oral Compositions for Treatment of Dry Mouth | LPO, TAS2R40, TAS2R60 | PTGS1 354/4885LTA4H 562/4885LDHA 626/4885 |
| US-20110104080-A1 | Oral Compositions for Treatment of Dry Mouth | LPO, TAS2R40, TAS2R60 | PTGS1 354/4885LTA4H 562/4885LDHA 626/4885 |
| US-20050234132-A1 | Production of cis-pellitorin and use as a flavouring | NISCH, CYP8B1, DLAT | PTGS1 1482/4885LTA4H 30/4885LDHA 1121/4885 |
| US-20050208084-A1 | Use of alkylamidomandelates as flavourings | HNMT, TAS2R7, PNMT | PTGS1 2281/4885LTA4H 1130/4885LDHA 3502/4885 |
| US-20080242740-A1 | AROMA COMPOSITIONS OF ALKAMIDES WITH HESPERETIN AND/OR 4-HYDROXYDIHYDROCHALCONES AND SALTS THEREOF FOR ENHANCING SWEET SENSORY IMPRESSIONS | TAS2R5, TAS2R20, TAS2R40 | PTGS1 2200/4885LTA4H 771/4885LDHA 1081/4885 |
| US-20080008660-A1 | Antimicrobially active compounds for treating bad breath | CAT, LPO, GPX1 | PTGS1 141/4885LTA4H 164/4885LDHA 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.